MCID: ADN016
MIFTS: 71

Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenocarcinoma

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 12 30 56 6 45 15 17 74
Adenocarcinomas 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:299
MeSH 45 D000230
NCIt 51 C2852
SNOMED-CT 69 35917007
UMLS 74 C0001418

Summaries for Adenocarcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinomas, is related to gastric papillary adenocarcinoma and bronchiolo-alveolar adenocarcinoma. An important gene associated with Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Carboplatin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1426)
# Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 34.4 ERBB2 TP53
2 bronchiolo-alveolar adenocarcinoma 34.3 CDH1 EGFR KRAS
3 papillary adenocarcinoma 34.3 CDH1 ERBB2 TP53
4 mucinous adenocarcinoma 34.3 CDKN2A EGFR KRAS MLH1
5 cervical adenocarcinoma 34.2 CDKN2A ERBB2 TP53
6 fallopian tube endometrioid adenocarcinoma 34.1 CDKN2A ERBB2
7 aggressive digital papillary adenocarcinoma 34.1 HRAS KRAS PIK3CA
8 mucinous lung adenocarcinoma 34.1 EGFR ERBB2 HRAS KRAS
9 urachal adenocarcinoma 34.0 BRAF KRAS
10 ovary adenocarcinoma 34.0 ERBB2 HRAS KRAS PIK3CA TP53
11 colon adenocarcinoma 34.0 APC CDH1 CTNNB1 KRAS MLH1
12 vulvar adenocarcinoma 34.0 RB1 TP53
13 cecum adenocarcinoma 34.0 HRAS KRAS MLH1
14 barrett's adenocarcinoma 33.9 CDKN2A ERBB2 KRAS TP53
15 endometrial adenocarcinoma 33.9 AKT1 CDKN2A CTNNB1 EGFR ERBB2 KRAS
16 pancreas adenocarcinoma 33.9 AKT1 CDH1 CDKN2A CTNNB1 EGFR EPCAM
17 barrett esophagus 33.9 APC CDKN2A ERBB2 TP53
18 nasal cavity adenocarcinoma 33.9 CDKN2A HRAS KRAS TP53
19 uterine corpus serous adenocarcinoma 33.8 ERBB2 PIK3CA TP53
20 colorectal adenocarcinoma 33.8 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
21 rare adenocarcinoma of the breast 33.5 AKT1 KRAS PIK3CA TP53
22 bile duct adenocarcinoma 33.5 AKT1 CDH1 EPCAM HRAS KRAS TP53
23 esophagus adenocarcinoma 33.5 ERBB2 HNF1A-AS1 SMAD4 TP53
24 adenosquamous carcinoma 33.3 EGFR KRAS PIK3CA TP53
25 breast adenocarcinoma 33.2 AKT1 EGFR ERBB2 H19 KRAS PIK3CA
26 suppression of tumorigenicity 12 33.1 AKT1 BRAF CDH1 CTNNB1 HRAS PIK3CA
27 renal cell carcinoma, papillary, 1 32.8 BRAF ERBB2 HRAS PIK3CA TP53
28 primary peritoneal carcinoma 32.6 EGFR ERBB2 TP53
29 adenoma 32.6 APC BRAF CTNNB1 KRAS MLH1 SMAD4
30 cystadenocarcinoma 32.6 AKT1 ERBB2 HRAS PIK3CA TP53
31 carcinosarcoma 32.6 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
32 colorectal adenoma 32.5 APC CTNNB1 HRAS KRAS MLH1 TP53
33 inflammatory breast carcinoma 32.5 CDH1 EGFR ERBB2
34 gastric adenocarcinoma 32.5 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
35 ovarian serous cystadenocarcinoma 32.5 AKT1 BRAF ERBB2 HRAS PIK3CA TP53
36 lung squamous cell carcinoma 32.4 AKT1 BRAF CDH1 EGFR HRAS KRAS
37 adenoid cystic carcinoma 32.4 AKT1 CDH1 CTNNB1 ERBB2 HRAS KRAS
38 lung cancer susceptibility 3 32.4 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
39 adenosquamous lung carcinoma 32.3 EGFR ERBB2 HRAS KRAS PIK3CA
40 serous cystadenocarcinoma 32.2 AKT1 ERBB2 HRAS PIK3CA TP53
41 esophageal cancer 32.2 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
42 lung cancer 31.7 AKT1 BRAF CDH1 CDKN2A EGFR EPCAM
43 hidradenocarcinoma 31.6 EGFR ERBB2 TP53
44 prostate cancer 31.5 AKT1 CDH1 CTNNB1 EGFR ERBB2 H19
45 small cell carcinoma 31.5 CDKN2A EGFR TP53
46 pancreatic cancer 31.4 AKT1 CDH1 CDKN2A CTNNB1 EGFR ERBB2
47 colitis 31.3 AKT1 CTNNB1 MLH1 SMAD4
48 endometrial cancer 31.2 AKT1 BRAF CDH1 CDKN2A CTNNB1 EGFR
49 small cell cancer of the lung 31.2 AKT1 CDKN2A EGFR PIK3CA RB1 TP53
50 bladder cancer 31.2 CDH1 CDKN2A EGFR ERBB2 H19 HNF1A-AS1

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

27 (show top 50) (show all 71)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.23 BRAF KRAS HRAS EGFR PIK3CA
2 Decreased viability GR00106-A-0 11.23 KRAS
3 Decreased viability GR00107-A-1 11.23 TGFBR2
4 Decreased viability GR00221-A-1 11.23 CDH1 KRAS AKT1 CDKN2A HRAS TGFBR2
5 Decreased viability GR00221-A-2 11.23 KRAS AKT1 HRAS PIK3CA
6 Decreased viability GR00221-A-3 11.23 AKT1 CDKN2A ERBB2 HRAS TGFBR2
7 Decreased viability GR00221-A-4 11.23 BRAF AKT1 CDKN2A ERBB2 TGFBR2 EGFR
8 Decreased viability GR00301-A 11.23 BRAF CDH1 ERBB4 KRAS
9 Decreased viability GR00342-S-1 11.23 ERBB4
10 Decreased viability GR00381-A-1 11.23 BRAF KRAS
11 Decreased viability GR00402-S-2 11.23 BRAF CDH1 ERBB4 KRAS AKT1 CDKN2A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.64 RB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.64 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.64 CTNNB1 SMAD4 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.64 BRAF
16 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.64 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.64 PIK3CA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.64 KRAS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.64 RB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.64 MLH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.64 MLH1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.64 APC
23 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.64 MLH1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.64 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.64 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.64 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.64 AKT1 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.64 BRAF PIK3CA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.64 KRAS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.64 RB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.64 APC CTNNB1 AKT1 BRAF KRAS PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.64 PIK3CA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.64 APC
34 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.64 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.64 MLH1 SMAD4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.64 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.64 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.64 APC
39 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.64 SMAD4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.64 RB1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.64 KRAS
42 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.64 KRAS
43 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.64 SMAD4
44 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.64 APC BRAF
45 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.64 BRAF
46 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.64 BRAF
47 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.64 SMAD4 AKT1 PIK3CA
48 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.64 SMAD4 RB1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.64 SMAD4
50 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.64 CTNNB1 BRAF

MGI Mouse Phenotypes related to Adenocarcinoma:

47 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.56 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
2 cellular MP:0005384 10.55 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
3 endocrine/exocrine gland MP:0005379 10.55 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
4 behavior/neurological MP:0005386 10.51 AKT1 APC BRAF CDKN2A CTNNB1 EPCAM
5 embryo MP:0005380 10.51 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
6 homeostasis/metabolism MP:0005376 10.5 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
7 digestive/alimentary MP:0005381 10.49 APC BRAF CDH1 CDKN2A CTNNB1 EGFR
8 growth/size/body region MP:0005378 10.49 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
9 immune system MP:0005387 10.46 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
10 mortality/aging MP:0010768 10.46 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
11 integument MP:0010771 10.45 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
12 hematopoietic system MP:0005397 10.42 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
13 craniofacial MP:0005382 10.4 APC BRAF CTNNB1 EGFR ERBB2 ERBB4
14 neoplasm MP:0002006 10.38 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
15 nervous system MP:0003631 10.36 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
16 muscle MP:0005369 10.34 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
17 liver/biliary system MP:0005370 10.26 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
18 normal MP:0002873 10.25 AKT1 APC BRAF CDH1 CTNNB1 EGFR
19 adipose tissue MP:0005375 10.24 AKT1 APC BRAF EGFR PIK3CA RB1
20 limbs/digits/tail MP:0005371 10.19 APC BRAF CTNNB1 EGFR ERBB2 KRAS
21 hearing/vestibular/ear MP:0005377 10.13 APC BRAF CTNNB1 EGFR KRAS RB1
22 no phenotypic analysis MP:0003012 10.13 CDH1 CDKN2A CTNNB1 EGFR EPCAM HRAS
23 reproductive system MP:0005389 10.13 AKT1 APC BRAF CDH1 CDKN2A CTNNB1
24 pigmentation MP:0001186 9.97 APC BRAF CDKN2A CTNNB1 EGFR KRAS
25 renal/urinary system MP:0005367 9.97 APC BRAF CTNNB1 EGFR HRAS KRAS
26 respiratory system MP:0005388 9.97 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
27 skeleton MP:0005390 9.8 AKT1 APC BRAF CDKN2A CTNNB1 EGFR
28 vision/eye MP:0005391 9.36 APC BRAF CDKN2A CTNNB1 EGFR KRAS

Drugs & Therapeutics for Adenocarcinoma

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
3
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 441203 84093 2767
5
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
6
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 23925 27284
7
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
9
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 443-48-1 4173
10
Clarithromycin Approved Phase 4 81103-11-9 84029
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
13
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 61825-94-3 6857599 5310940 9887054 43805
14
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
15
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
16
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
17
Cefazolin Approved Phase 4,Phase 3 25953-19-9 656510 33255
18
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
19
Propranolol Approved, Investigational Phase 4,Phase 2,Early Phase 1,Not Applicable 525-66-6 4946
20
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
21
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
22 Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
23
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
24
acetic acid Approved Phase 4,Phase 2,Not Applicable 64-19-7 176
25
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177 70789204
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
27
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
28
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
29
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
30
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
31
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
32
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 198153-51-4 5360545
33
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
34
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154361-50-9 60953
35
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
36
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
37
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
38
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 216974-75-3
39
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
40
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 51-43-4 5816
41
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 329-65-7 838
42
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 56420-45-2 41867
43
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 2 142340-99-6 60871
44
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
45
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
46
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 68538-85-2
47
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
48
Zinc Approved, Investigational Phase 4,Phase 1,Not Applicable 7440-66-6 32051
49
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
50
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 7819)
# Name Status NCT ID Phase Drugs
1 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
2 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
3 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
4 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
5 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
7 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Unknown status NCT02426034 Phase 4 Apatinib
8 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
9 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
10 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
11 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
12 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
13 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
14 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
15 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
16 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
17 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
18 RFA for Small HCC With No-touch Technique Using Octopus Electrode Unknown status NCT02832882 Phase 4
19 RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode Unknown status NCT02806076 Phase 4
20 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
21 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
22 Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma Unknown status NCT02504983 Phase 4 sorafenib
23 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
24 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
25 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
26 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
27 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
28 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
29 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
30 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
31 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
32 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
33 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
34 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
35 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Unknown status NCT01206764 Phase 4 RAD001
36 Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
37 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
38 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
39 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
40 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
41 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
42 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
43 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
44 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
45 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
46 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
47 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
48 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
49 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
50 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: adenocarcinoma

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

# Genetic test Affiliating Genes
1 Adenocarcinoma 30

Anatomical Context for Adenocarcinoma

MalaCards organs/tissues related to Adenocarcinoma:

42
Lung, Prostate, Liver, Colon, Breast, Kidney, Pancreas

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 28720)
# Title Authors Year
1
Case presentation of acanthosis nigricans diagnosed with gastric adenocarcinoma. ( 30836438 )
2019
2
TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells. ( 30902544 )
2019
3
Clinicopathological significance and prognostic role of chemokine receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis and literature review. ( 30902754 )
2019
4
Cutaneous Toxicity after Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. ( 30902915 )
2019
5
≤ Cyclin D1 protein affecting global women's health by regulating HPV mediated adenocarcinoma of the uterine cervix. ( 30903019 )
2019
6
Morphological classification of pre-invasive lesions and early-stage lung adenocarcinoma based on CT images. ( 30903336 )
2019
7
Impact of calcifications on diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma. ( 30903611 )
2019
8
Clinical usefulness of gastric adenocarcinoma predictive long intergenic noncoding RNA in human malignancies: A meta-analysis. ( 30904361 )
2019
9
Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study. ( 30905320 )
2019
10
Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis. ( 30905549 )
2019
11
Intrasplenic Pancreatic Pseudocyst after Chemoradiation of a Pancreatic Adenocarcinoma Mimicking Progressive Disease: A Case Report and Review of the Literature. ( 30906608 )
2019
12
Dickkopf-1 (DKK1) promotes tumor growth via Akt-phosphorylation and independently of Wnt-axis in Barrett's associated esophageal adenocarcinoma. ( 30906632 )
2019
13
SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. ( 30906634 )
2019
14
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. ( 30906655 )
2019
15
Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection. ( 30906746 )
2019
16
Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. ( 30906838 )
2019
17
Co-existing monophasic teratoma and uterine adenocarcinoma in a female dog. ( 30907028 )
2019
18
High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma. ( 30907518 )
2019
19
Diagnosis of Combined Adenocarcinoma Small Cell Lung Cancer By Endobronchial Ultrasound Transbronchial Needle Aspiration. ( 30908396 )
2019
20
The subpopulation of CD44-positive cells promoted tumorigenicity and metastatic ability in lung adenocarcinoma. ( 30908413 )
2019
21
Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review ( 30909661 )
2019
22
Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. ( 30909965 )
2019
23
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. ( 30911859 )
2019
24
UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells. ( 30911937 )
2019
25
Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients ( 30912007 )
2019
26
Establishment and Analysis of a 3D Co-Culture Spheroid Model of Pancreatic Adenocarcinoma for Application in Drug Discovery. ( 30912022 )
2019
27
Prognostic Significance of High Androgen Receptor Expression in Prostatic Acinar Adenocarcinoma ( 30912411 )
2019
28
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. ( 30913304 )
2019
29
Identification of tumor suppressor microRNAs by integrative microRNA and mRNA sequencing of matched tumor-normal pairs in lung adenocarcinoma. ( 30913346 )
2019
30
Sulfenamide derivatives can improve transporter-mediated cellular uptake of metformin and induce cytotoxicity in human breast adenocarcinoma cell lines. ( 30913467 )
2019
31
A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib. ( 30914311 )
2019
32
Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma. ( 30914315 )
2019
33
Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma. ( 30914682 )
2019
34
Risk of lung adenocarcinoma from smoking and radiation arises in distinct molecular pathways. ( 30915466 )
2019
35
Gprotein-coupled estrogen receptor 30 and extracellular signal-regulated kinase 1/2 in endometrial adenocarcinoma. ( 30915827 )
2019
36
Triiodothyronine (T3) upregulates the expression of proto-oncogene TGFA independent of MAPK/ERK pathway activation in the human breast adenocarcinoma cell line, MCF7. ( 30916164 )
2019
37
Up-regulation of CKAP2L expression promotes lung adenocarcinoma invasion and is associated with poor prognosis. ( 30863084 )
2019
38
The prognostic value of Tiam1 correlates with its roles in epithelial-mesenchymal transition progression and angiogenesis in lung adenocarcinoma. ( 30863182 )
2019
39
MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). ( 30863319 )
2019
40
The difference and relationship of CD4+ and CD8+ tumour infiltrating lymphocytes in lung adenocarcinoma. ( 30863488 )
2019
41
Regionally surgical resection of stage-IV adenocarcinoma acquired tyrosine kinases inhibitor-resistance. ( 30863599 )
2019
42
Treatment of stage IIIA-N2 EGFR-mutant non-small cell lung adenocarcinoma. ( 30863601 )
2019
43
Troisier sign and Virchow node: the anatomy and pathology of pulmonary adenocarcinoma metastasis to a supraclavicular lymph node. ( 30863728 )
2019
44
Use of tunnel endoscopy for diagnosis of obscure submucosal esophageal adenocarcinoma: A case report and review of the literature with emphasis on causes of esophageal stenosis. ( 30863768 )
2019
45
Validation of the eighth edition of the American Joint Committee on Cancer staging system and proposal of an improved staging system for pancreatic ductal adenocarcinoma. ( 30863807 )
2019
46
Extracellular vesicle‑delivered miR‑505‑5p, as a diagnostic biomarker of early lung adenocarcinoma, inhibits cell apoptosis by targeting TP53AIP1. ( 30864684 )
2019
47
Downregulation of estrogen receptor β inhibits lung adenocarcinoma cell growth. ( 30864727 )
2019
48
Analysis of microRNA expression profiles reveals a 5‑microRNA prognostic signature for predicting overall survival time in patients with gastric adenocarcinoma. ( 30864737 )
2019
49
"Laparoscopic Para-Aortic Lymph Node Sampling" First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. ( 30864878 )
2019
50
Micropapillary Cervical Adenocarcinoma: A Clinicopathologic Study of 44 Cases. ( 30864975 )
2019